SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-21-000034
Filing Date
2021-05-07
Accepted
2021-05-07 09:28:42
Documents
6
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 2021 FIRST QUARTER 6-K q12021form6-k.htm 6-K 27853
2 2021 FIRST QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsmarch312021.htm EX-99.1 354011
3 2021 FIRST QUARTER MD&A ex992-q12021mda.htm EX-99.2 181523
4 Q1 2021 CERTIFICATION CEO ex993-q12021certificationx.htm EX-99.3 14731
5 Q1 2021 CERTIFICATION CFO ex994-q12021certificationx.htm EX-99.4 14628
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
  Complete submission text file 0001129928-21-000034.txt   1033226
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 21900681
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences